Tri- Gene Test
Traditional screening misses the diagnosis of Down's syndrome in 10-35% cases with a false positive rate of 5-7%, making the mother undergo unnecessary invasive tests that can cause 0.5- 1% fetal loss.
Tri- Gene is a prenatal diagnosis/screening test without risk and high accuracy and also avoid invasive test.Comparison of Traditional Screening and Diagnosis Technologies:
|Method||Non/Invasive||Pregnancy(W)||Risk & Detection Rate|
|First-Trimester Serum Screening||Non/Invasive||11/13||65%?70% Detection Rate|
|Second-Trimester Serum Screening||Non/Invasive||15/19||69%/81% Detection Rate|
|Fetal Nuchal Translucency (NT)||Non/Invasive||11/13||64%/70% Detection Rate|
|Serum Integrated Screen||Non/Invasive||11/13 & 15/19||85%/88% Detection Rate|
|Serum integrated screen + NT||Non/Invasive||11/13 & 15/19||94%/96% Detection Rate|
|Amniocentesis||Invasive||16/21||0.5/1% Miscarriage Permission Required|
|Chorionic villi aspiration sampling (CVS)||Invasive||10/13||1/2% Miscarriage Permission Required|
|Percutaneous umbilical blood sampling (PUBS)||Invasive||18/24||1/2% Miscarriage Permission Required|
|Tri- Gene||Non/Invasive||12- 24||No Miscarriage Risk >99% Detection Rate|
|Accuracy:||The test detects >99% of pregnancies affected by Down syndrome. The false positive rate is <1%.|
|Testing Period:||The test can be done between 12 weeks to 24 weeks of gestation.|
|Sample Needed:||Only 5ml maternal peripheral blood is needed.|
|Reporting Time:||The report is available within 2 weeks in 90% cases.|
- Non-Invasive: only 5 mL maternal peripheral blood is needed. Therefore, there is no risk of intrauterine infection and miscarriage.
- Highly Accurate: 100% sensitivity and 99.9% specificity.
- Early-Test: can be performed at the early pregnancy (~12 weeks), which allows early detection for a better clinical decision.
- Report: available within 2 weeks.
- Inclusivity: All chromosomal aneuploidies could be detected in one test.
- Those that wish to have non-invasive fetal aneuploidies test for trisomy21, 18 and 13.
- Those whose age is 35 or above and does not choose to receive invasive prenatal tests.
- Those whose serum biochemical tests and ultrasound examinations suggest high risk of chromosome aneuploidies at the first and second trimester.
- Those that has contraindication of invasive prenatal testing, such as placenta previa, risks of miscarriage, HBV infection and HIV infection, etc.
- Those that received IVF, or previously suffered from habitual abortion.